Related Experiment Videos
Endothelial protective effects of preconditioning
Karine Laude1, Philippe Beauchamp, Christian Thuillez
1INSERM E9920, IFRMP 23, Department of Pharmacology, Faculté de Médecine, Rouen University, 22 Bd. Gambetta, 76183 CEDEX 1, France.
Insights
Cardiac preconditioning protects the coronary endothelium from ischemia-reperfusion injury by reducing inflammation and improving nitric oxide (NO) function. This offers a promising therapeutic target for heart conditions.
Area of Science:
- Cardiovascular Biology
- Endothelial Function
- Ischemia-Reperfusion Injury
Background:
- Cardiac ischemia-reperfusion (I/R) injury affects not only heart muscle cells (myocytes) but also the coronary endothelium.
- Endothelial dysfunction, marked by reduced nitric oxide (NO)-dependent relaxations, is a key consequence of I/R.
- The endothelium and NO are crucial for regulating vascular tone and immune cell interactions, making endothelial protection a vital therapeutic goal.
Purpose of the Study:
- To investigate the protective effects of early and delayed preconditioning on coronary endothelial cells following I/R.
- To elucidate the underlying mechanisms of endothelial protection mediated by preconditioning.
- To identify potential therapeutic targets for mitigating I/R-induced endothelial dysfunction.
Main Methods:
- Review of existing studies on early and delayed preconditioning in the context of cardiac I/R.
- Analysis of preconditioning's impact on endothelial adhesion molecules and neutrophil-endothelial interactions.
- Examination of the roles of mediators like adenosine, bradykinin, NO, and free radicals in preconditioning.
Main Results:
- Both early and delayed preconditioning demonstrate protective effects against endothelial dysfunction post-I/R.
- Preconditioning reduces neutrophil adhesion to endothelial cells, likely by inhibiting adhesion molecule expression.
- Early preconditioning involves mediators such as adenosine, bradykinin, NO, and free radicals, activating protein kinase C and KATP channels.
- Delayed preconditioning relies on NO and free radicals, leading to increased NO production and reduced neutrophil adhesion.
Conclusions:
- Cardiac preconditioning offers significant protection to the coronary endothelium against I/R injury.
- Preconditioning mechanisms involve complex interactions of NO and free radicals, ultimately enhancing endothelial function.
- Further research into these triggers and mediators can lead to novel therapeutics for both cardiac and vascular protection.
Abstract:
The consequences of cardiac ischemia-reperfusion are not limited to myocytes but also extend to the coronary endothelium, where they are characterized by decreased nitric oxide (NO)-dependent relaxations. Given the essential role of the endothelium and NO in the regulation of vascular tone as well as platelet and leukocyte function, protection of coronary endothelial cells is an important therapeutic target. In this context, several studies have shown that both early and delayed preconditioning may prevent endothelial dysfunction after index ischemia-reperfusion. This endothelial protection most likely results from the inhibitory effects of preconditioning on expression of endothelial adhesion molecules, resulting in reduced neutrophil-endothelial interactions. The mechanisms of early endothelial preconditioning resemble those described at the level of the myocytes, and may involve mediators such as adenosine, bradykinin, NO and free radicals, together with activation of protein kinase C and opening of ATP-sensitive potassium channels. With regard to delayed preconditioning, recent studies have shown that both NO and free radicals are involved as triggers of this second window of endothelial protection. The complex interactions between these two radical species ultimately lead to a delayed increase in NO production, most likely responsible for the decreased adhesion of neutrophils to endothelial cells. Further identification of the triggers and mediators of this endothelial protection will allow the development of new therapeutic agents targeting both the myocardium and the coronary vasculature.